




Institute  
and Faculty  
of Actuaries

# Discontinuation of LIBOR and What This Means for Insurers

Ben Mabley, Goldman Sachs  
Henrik Wijkander, Phoenix



# Contents

- I. LIBOR – A Short Background
- II. SONIA – New Benchmark Risk-Free Compliant Rate?
- III. LIBOR / SONIA Market Overview
- IV. An Insurer's Perspective

# LIBOR – A Short Background

---



# LIBOR – A High Level Overview

1986

year LIBOR was introduced



2021

year after which the FCA will no longer compel panel banks to submit to LIBOR



\$370T

total outstanding notional of **IBOR** exposures across markets and currencies



\$300T

total outstanding notional of **USD LIBOR and EURIBOR** exposures (\$150T for each rate) globally



\$150T

Notional **Interest Rate Derivatives** trading volume linked to LIBOR in 2018



11:55am

Time (GMT) at which LIBOR is normally published for each currency and tenor combination on every business day



97%

portion of **syndicated loans in the US market** (~\$3.4T in outstanding volumes) that reference USD LIBOR




3m


**benchmark tenor** most widely referenced, by volume



# LIBOR – How Big Is the Problem for UK Insurers?



LIBOR-Linked Derivatives Notional Summary – 2015 PRA Returns (£bn)



$\Sigma$  LIBOR-linked Derivatives = £323bn

Source: PRA Returns 2015.

# LIBOR Phase Out – How Did it Happen?

## Current Position

### Relevance

Limitations in the relevance of LIBOR as a benchmark rate

### Sustainability & Stability

Questions around the sustainability and stability of LIBOR in stressed market conditions, given the lack of an active and highly liquid underlying market

### LIBOR Manipulation

Instances of LIBOR manipulation in the 2008 financial crisis and the 2012 LIBOR scandal

IMPACT

## Events



**2014**  
FSB recommend review of IBOR Rates

**July 2017:**  
FCA states they will not compel LIBOR submission after 2021


**July 2018:**  
Bailey reiterates LIBOR discontinuation and need for market preparedness

# **SONIA – New Benchmark Risk-Free Compliant Rate?**

---








# Global Interest Rate Benchmarks






# Risk Free Rates (RFR) Working Groups

Jurisdiction	Working Group	Alternative RFR	Rate Administration	Secured vs. Unsecured	First Publication
 US	Alternative Reference Rates Committee	Secured Overnight Financing Rate (SOFR)	Federal Reserve Bank of New York	Secured	3 April 2018
 UK	Working Group on Sterling Risk-Free Reference Rates	Reformed Sterling Overnight Index Average (SONIA)	Bank of England	Unsecured	23 April 2018
 Europe	Working Group on Risk-Free Reference Rates for the Euro Area	Euro Short-Term Rate (€STR)	European Central Bank	Unsecured	Anticipated October 2019
 Switzerland	The National Working Group on CHF Reference Rates	Swiss Average Rate Overnight (SARON)	SIX Swiss Exchange	Secured	Already published prior to 2018
 Japan	Study Group on Risk-Free Reference Rates	Tokyo Overnight Average Rate (TONAR)	Bank of Japan	Unsecured	Already published prior to 2018

# Timeline: Future Events in the LIBOR Transition



 Key Events For UK Insurers


# LIBOR / SONIA Market Overview

---




# LIBOR / SONIA – Curve Distribution

## SONIA & LIBOR Curves (Day on Day)



## SONIA & LIBOR Curves (Month on Month)




Source: Goldman Sachs Securities Division as of January 2019. Indicative terms only. Transactions subject to internal approvals and may change. Goldman Sachs does not provide tax, accounting, regulatory or legal advice to our clients, and all clients are advised to consult with their own advisers regarding any potential investment/transaction. This material is for discussion purposes only, and does not purport to contain a comprehensive analysis of the risk/rewards of any idea or strategy. This has been prepared in good faith by the desk

# LIBOR / SONIA Basis – Recent History



Source: Goldman Sachs Securities Division as of January 2019. Indicative terms only. Transactions subject to internal approvals and may change. Goldman Sachs does not provide tax, accounting, regulatory or legal advice to our clients, and all clients are advised to consult with their own advisers regarding any potential investment/transaction. This material is for discussion purposes only, and does not purport to contain a comprehensive analysis of the risk/rewards of any idea or strategy. Past performance is not indicative of future results.

# LIBOR / SONIA – Market Participants



# **An Insurer's Perspective**



# Preparing for IBOR Transition

## 'Dear CEO Letter'



- The PRA & FCA wrote to the CEOs of large banks and insurance companies in Sep 2018 in relation to the likely discontinuation of LIBOR
- The purpose of the letter was to seek assurance that senior managers & boards understand the risks associated with the transition to alternative reference rates by the end of 2021

## Overview of IBOR Transition Projects






# Question Marks over SII RFR Curve



# Capital Considerations



# Overview of General Transition Process



# Implementation Considerations for Post-IBOR Hedging Strategy

## Regulatory Timeframe

- Statements by the FCA suggest LIBOR can be expected to be discontinued by the end of 2021
- Lack of clear timeline from EIOPA on transition for RFR
- EMIR regulations require IM on all new bilateral swaps (including SONIA swaps) entered into from September 2020

## Basis Risk

- What is the size of the LIBOR/SONIA basis risk and potential capital impact of transitioning to SONIA-based instruments before SII discount curve is redefined?

## Market Liquidity

- How much is transacted per week across relevant tenors?
- What's an acceptable bid/offer level and suitable execution timeframe?

## Transaction Costs


- Where is LIBOR/SONIA basis trading vs expected fallback levels?
- Where does the legacy hedges break even?

## Collateral Requirements

- Bilateral vs centrally cleared contracts

# ISDA Consultation on IBOR Fallback

Term-rate Adjustments		Credit-spread Adjustments	
	Respondents' Rankings	Pros / Cons Discussed by Respondents	
<b>Spot Overnight Rate</b>	<ul style="list-style-type: none"> <li>Preferred by only 2 respondents (&lt;1.5%)</li> </ul>	<ul style="list-style-type: none"> <li>- Lacks any term structure, associated with high volatility and could have large economic impact</li> </ul>	<b>Forward Approach</b>
<b>Convexity-adjusted Overnight Rate</b>	<ul style="list-style-type: none"> <li>Preferred by only 2 respondents (&lt;1.5%)</li> </ul>	<ul style="list-style-type: none"> <li>- Incompatible with other OIS derivatives</li> <li>- Vulnerable to manipulation and litigation risk</li> </ul>	
<b>Compounded Setting in Arrears Rate</b>	<ul style="list-style-type: none"> <li>Preferred by the vast majority of respondents (almost 90%)</li> </ul>	<ul style="list-style-type: none"> <li>+ Reflects actual daily interest rate movements during the relevant period</li> <li>+ Less volatile than spot overnight and mirrors the structure of the OIS market</li> <li>- Info needed to determine the rate not available at the start of the period, posing operational challenges that may impede take-up</li> </ul>	<b>Historical Mean/Median Approach</b>
<b>Compounded Setting in Advance Rate</b>	<ul style="list-style-type: none"> <li>Preferred by 11 respondents (&lt;8%)</li> </ul>	<ul style="list-style-type: none"> <li>+ Similar advantages to setting in arrears</li> <li>+ Data is available at the start of the period, so could be operationally easier</li> <li>- Backward-looking nature is disadvantageous and could result in value transfers</li> </ul>	
			<b>Spot-Spread Approach</b>
			<ul style="list-style-type: none"> <li>Preferred by 1/3 of respondents but strictly opposed by others</li> </ul>
			<ul style="list-style-type: none"> <li>+ Would minimize value transfers at the time of the trigger (potentially reducing legal risks) and should reflect current market spreads</li> <li>- Relies on market liquidity and data which may not exist at the time of trigger, in addition to being operationally complex</li> <li>- Vulnerable to market distortions and manipulation around the time of transition</li> <li>- Could lock in a spread based on a disrupted market</li> </ul>
			<ul style="list-style-type: none"> <li>Preferred by a significant majority (over 2/3) across different respondent groups</li> <li>Most who preferred the forward approach ranked the historical mean/median approach 2nd and would support it</li> </ul>
			<ul style="list-style-type: none"> <li>+ Robust and most resistant to manipulation</li> <li>+ Shorter lookback period could better reflect market conditions and have data readily available, be more resistant to manipulation, and minimize value transfer</li> <li>- May create value transfer or market disruption at time of trigger by not reflecting contemporaneous market conditions, as well as potential hedging issues</li> <li>- One-year transition would be operationally complex</li> </ul>
			<ul style="list-style-type: none"> <li>Preferred by only 4 respondents (&lt;3%)</li> </ul>
			<ul style="list-style-type: none"> <li>+ Simple and somewhat resistant to manipulation (though others pointed out it may still be susceptible to manipulation)</li> <li>- Might capture unusual market conditions during a period of market dislocation</li> </ul>

 Preference indicated by majority of respondents

 Details to follow

Source: "Anonymized Narrative Summary of Responses to the ISDA Consultation on Term Fixings and Spread Adjustment Methodologies" (The Brattle Group, prepared for ISDA, 20 December 2018)


# ISDA Fallback – Illustrative Calculation

## Example Assumptions – Historical Mean Spread applied to an adjusted RFR calculated in Arrears

- Underlying IBOR = 3m GBP LIBOR (“3mL”)
- Alternative RFR = **SONIA**
- Historical lookback period selected by ISDA = **3 years**
- Announcement of LIBOR cessation by the FCA (the “**trigger**” event) occurs **1 Jan 2021** (i.e., the date prior to announcement, and the most recent data point included in the historical lookback period, is **31 Dec 2019**); LIBOR will no longer be published after **1 Jan 2022**

Lookback period from 1 <sup>st</sup> Jan 2022	Implied SONIA3s (bps)
3y	15.7
5y	13.7
6y	14.0
7y	13.7
10y	16.2

## Illustration of Credit Spread Calculation



# LIBOR / SONIA Transition Strategies

## Key Strategies and Considerations

	Description	Pros	Cons	Cost Considerations	IM	VM
<b>1 Do Nothing</b>	<ul style="list-style-type: none"> <li>Leave legacy position and LIBOR sensitivities</li> <li>Rely on fallback provisions in 2021</li> </ul>	<ul style="list-style-type: none"> <li>✓ No outright transaction costs incurred</li> </ul>	<ul style="list-style-type: none"> <li>✗ Complete reliance on ISDA fallback</li> <li>✗ Significant volatility if there is trading ahead of the backdrop</li> <li>✗ Potentially high cost of switching later</li> </ul>	<ul style="list-style-type: none"> <li>Uncertain. Exposure to basis widening i.e. lock in a worse rate on transition from LIBOR to SONIA</li> </ul>	✗	<ul style="list-style-type: none"> <li>✓</li> <li>Cash and Gilts</li> </ul>
<b>2 Switch from 6mL to SONIA Cleared Swaps</b>	<ul style="list-style-type: none"> <li>Unwind legacy LIBOR swap (Insurer rec cash)</li> <li>Replace with SONIA cleared via LCH</li> </ul>	<ul style="list-style-type: none"> <li>✓ Reduction in bilateral counterparty risk</li> <li>✓ No reliance on ISDA fallback</li> <li>✓ Industry trend towards clearing</li> </ul>	<ul style="list-style-type: none"> <li>✗ Potential own funds volatility from moving part of positions to SONIA before the liability benchmark change</li> </ul>	<ul style="list-style-type: none"> <li>Unwinding a position under cash and gilt CSA carries a [SONIA + 10] cost</li> <li>Basis risk charge</li> </ul>	✓	<ul style="list-style-type: none"> <li>✓</li> <li>Cash Only</li> </ul>
<b>3 Switch from 6mL to SONIA Bilateral Swaps</b>	<ul style="list-style-type: none"> <li>Unwind legacy LIBOR swaps</li> <li>Replicate risk with a smaller portfolio of SONIA swaps (reducing the overall notional and releasing any NPV)</li> </ul>	<ul style="list-style-type: none"> <li>✓ Ability to continue posting Gilts as collateral in a bilateral netting set</li> <li>✓ Release cash/MtM from existing swap positions</li> </ul>	<ul style="list-style-type: none"> <li>✗ Adding on market bilateral swaps results in a charge given balance sheet impact of increased probability of posting Gilts</li> </ul>	<ul style="list-style-type: none"> <li>Re-coupons a position under cash and gilt CSA carries an increased cost</li> <li>Basis risk charge</li> </ul>	✗ Subject to Margin Rules	<ul style="list-style-type: none"> <li>✓</li> <li>Cash and Gilts</li> </ul>
<b>4 Bilateral Basis Swap Overlay</b>	<ul style="list-style-type: none"> <li>Leave all legacy positions unchanged, retaining LIBOR sensitivities</li> <li>Directly hedge LIBOR / SONIA basis risk by entering into an ATM basis swap (6m£ LIBOR vs SONIA)</li> </ul>	<ul style="list-style-type: none"> <li>✓ Swaps stay bilateral so no liquidity outlay</li> <li>✓ No need to touch back-book of swaps</li> </ul>	<ul style="list-style-type: none"> <li>✗ Reliance on ISDA fallback</li> <li>✗ Need to rebalance and OIS/LIBOR risk changes due to MtM in existing swaps</li> <li>✗ Does not release cash/MtM from existing swap positions</li> </ul>	<ul style="list-style-type: none"> <li>Basis risk charge</li> <li>Restructuring post in-scope for margin rules would necessitate posting IM</li> </ul>	✗ Subject	<ul style="list-style-type: none"> <li>✓</li> <li>Cash and Gilts</li> </ul>
<b>5 Gilts</b>	<ul style="list-style-type: none"> <li>Unwind LIBOR exposure and replace MtM with Gilts</li> </ul>	<ul style="list-style-type: none"> <li>✓ No further linkage to LIBOR and no necessitation on document changes</li> </ul>	<ul style="list-style-type: none"> <li>✗ May not be able to maintain same PV01 given initial cash outlay</li> <li>✗ Incur Bid/Offer on Gilts</li> </ul>	<ul style="list-style-type: none"> <li>Initial Cash Outlay</li> </ul>	NA	NA

**Any Questions?**

---





# Disclaimers



- **This message has been prepared by personnel in the Securities Division of one or more affiliates of The Goldman Sachs Group, Inc. ("Goldman Sachs") and is not the product of Global Investment Research. It is not a research report and is not intended as such.**
  - **Non-Reliance and Risk Disclosure:** This material is for the general information of our clients and is a solicitation of derivatives business generally, only for the purposes of, and to the extent it would otherwise be subject to, CFTC Regulations 1.71 and 23.605. This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. We are not soliciting any specific action based on this material. For the purposes of U.S. rules and regulations, it does not constitute a recommendation or take into account the particular investment objectives, financial conditions, or needs of individual clients. Before acting on this material, you should consider whether it is suitable for your particular circumstances and, if necessary, seek professional advice. The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide to future performance. Future returns are not guaranteed, and a loss of original capital may occur. We do not provide tax, accounting, or legal advice to our clients, and all investors are advised to consult with their tax, accounting, or legal advisers regarding any potential investment. **The material is based on information that we consider reliable, but we do not represent that it is accurate, complete and/or up to date, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only and only represent the views of the author and not those of Goldman Sachs, unless otherwise expressly noted.**
  - **Conflict of Interest Disclosure:** We are a full-service, integrated investment banking, investment management, and brokerage firm. The professionals who prepared this material are paid in part based on the profitability of The Goldman Sachs Group, Inc., which includes earnings from the firm's trading, capital markets, investment banking and other business. They, along with other salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein or the opinions expressed in research reports issued by our Research Departments, and our market making, investing and lending businesses may make investment decisions that are inconsistent with the views expressed herein. In addition, the professionals who prepared this material may also produce material for, and from time to time, may advise or otherwise be part of our trading desks that trade as principal in the securities mentioned in this material. This material is therefore not independent from our interests, which may conflict with your interests. We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives (including options) thereof in, and act as market maker or specialist in, and serve as a director of, companies mentioned in this material. In addition, we may have served as manager or co manager of a public offering of securities by any such company within the past three years.
  - **Not a Fiduciary:** To the extent this material is provided to an employee benefit plan or account subject to the Employee Retirement Income Security Act of 1974, as amended ("ERISA") or Section 4975 of the Internal Revenue Code of 1986, as amended (the "Code") (each, a "Benefit Plan Investor"), by accepting this material such Benefit Plan Investor will be deemed to have represented, warranted and acknowledged that (1) the Benefit Plan Investor is represented by a fiduciary that is independent of Goldman Sachs and its affiliates (the "Independent Fiduciary"), (2) the Independent Fiduciary is a bank (as defined in section 202 of the Investment Advisers Act of 1940 (the "Advisers Act")) or a similar institution that is regulated and supervised and subject to periodic examination by a State or Federal agency; an insurance carrier which is qualified under the laws of more than one State to perform the services of managing, acquiring or disposing of assets of a plan; an investment adviser registered under the Advisers Act or, if not registered as an investment adviser under the Advisers Act by reason of paragraph (1) of section 203A, is registered as an investment adviser under the laws of the State in which it maintains its principal office and place of business; a broker-dealer registered under the Securities Exchange Act of 1934; or an Independent Fiduciary that holds or has under management or control total assets of at least \$50 Million; (3) the Independent Fiduciary is capable of evaluating investment risks independently, both in general and with regard to the information contained in this material; (4) the Independent Fiduciary is a fiduciary under ERISA and/or the Code with respect to, and is responsible for exercising independent judgment in evaluating, the information contained in this material; (5) neither Goldman Sachs nor its affiliates are undertaking to provide impartial investment advice, or to give advice in a fiduciary capacity, in connection with the information contained in this material or with respect to any Benefit Plan Investor's subsequent investment decisions; and (6) any financial interest of Goldman Sachs and its affiliates is or has been disclosed. To the extent this material is provided to any other recipient, this material is provided solely on the basis that the recipient has the capability to independently evaluate investment risk and is exercising independent judgment in evaluating investment decisions in that its investment decisions will be based on its own independent assessment of the opportunities and risks presented by a potential investment, market factors and other investment considerations.
- Not a Municipal Advisor:** Except in circumstances where Goldman Sachs expressly agrees otherwise in writing, Goldman Sachs is not acting as a municipal advisor and the opinions or views contained herein are not intended to be, and do not constitute, advice, including within the meaning of Section 15B of the Securities Exchange Act of 1934.
- **Legal Entities Disseminating this Material:** This material is disseminated in Australia by Goldman Sachs Australia Pty Ltd (ABN 21 006 797 897); in Canada by either Goldman Sachs Canada Inc. or Goldman Sachs & Co. LLC; in Hong Kong by Goldman Sachs (Asia) L.L.C. or by Goldman Sachs Asia Bank Limited, a restricted licence bank; in Japan by Goldman Sachs Japan Co., Ltd.; in the Republic of Korea by Goldman Sachs (Asia) L.L.C., Seoul Branch; in New Zealand by Goldman Sachs New Zealand Limited; in Singapore by Goldman Sachs (Singapore) Pte. (Company Number: 198602165W), by Goldman Sachs Futures Pte. Ltd (Company Number: 199004153Z) or by J.Aron & Company (Singapore) Pte (Company Number: 198902119H); in India by Goldman Sachs (India) Securities Private Limited, Mumbai Branch; in Europe by Goldman Sachs International ("GSI"), unless stated otherwise; in France by Goldman Sachs Paris Inc. et Cie and/or GSI; in Germany by GSI and/or Goldman Sachs Bank Europe SE; in the Cayman Islands by Goldman Sachs (Cayman) Trust, Limited; in Brazil by Goldman Sachs do Brasil Banco Múltiplo S.A.; and in the United States of America by Goldman Sachs & Co. LLC (which is a member of FINRA, NYSE and SIPC) and by Goldman Sachs Bank USA. You may obtain information about SIPC, including the SIPC brochure, by contacting SIPC (website: <http://www.sipc.org/>; phone: 202-371-8300). GSI, which is authorised by the Prudential Regulation Authority ("PRA") and regulated by the Financial Conduct Authority ("FCA") and the PRA, has approved this material in connection with its distribution in the United Kingdom and European Union. GSI, whose registered office is at Peterborough Court, 133 Fleet Street, London EC4A 2BB, appears in the FCA's Register (Registration No.: 142888). GSI is registered as a Private Unlimited Company in England and Wales (Company Number: 2263951) and its VAT registration number is GB 447 2649 28. GSI is subject to the FCA and PRA rules and guidance, details of which can be found on the websites of the FCA and PRA at [www.fca.org.uk](http://www.fca.org.uk) and [www.bankofengland.co.uk/pru](http://www.bankofengland.co.uk/pru). The FCA is located at 25 The North Colonnade, Canary Wharf, London E14 5HS, and the PRA is located at Bank of England, 20 Moorgate, London EC2R 6DA. Unless governing law permits otherwise, you must contact a Goldman Sachs entity in your home jurisdiction if you want to use our services in effecting a transaction in the securities mentioned in this material. This material is not for distribution to retail clients, as that term is defined under The European Union Markets in Financial Instruments Directive (2014/65/EU), and any investments, including derivatives, mentioned in this material will not be made available by us to any such retail client.

- **Phone recording:** Telephone conversations with Goldman Sachs personnel may be recorded and retained.
- **Reproduction and Re-Distribution:** Without our prior written consent, no part of this material may be (i) copied, photocopied or duplicated in any form by any means or (ii) redistributed. Notwithstanding anything herein to the contrary, and except as required to enable compliance with applicable securities law, you (and each of your employees, representatives and other agents) may disclose to any and all persons the U.S. federal income and state tax treatment and tax structure of the transaction and all materials of any kind (including tax opinions and other tax analyses) that are provided to you relating to such tax treatment and tax structure, without Goldman Sachs imposing any limitation of any kind.
- **Information Not for Further Dissemination:** To the extent this communication contains Goldman Sachs' pricing information, such pricing information is proprietary and/or confidential and is provided solely for the internal use of the intended recipient(s). You are notified that any unauthorized use, dissemination, distribution or copying of this communication or its contents, including pricing information, in whole or in part, is strictly prohibited. Further, unless prohibited by local law, any use, review or acceptance of this information is subject to and manifests your agreement with Goldman Sachs to use such information only in accordance with the terms set forth above. Goldman Sachs has caused its proprietary information to be delivered to you in reliance upon such agreement.
- **Receipt of Orders:** An order sent to Goldman Sachs by email or instant message is not deemed to be received by Goldman Sachs until a Goldman Sachs representative verifies the order details with a phone call to the client or acknowledges receipt of the order via email or instant message to the client. Goldman Sachs does not accept client orders sent via fax or voicemail systems.
- **Not a Valuation:** Values herein are not customer valuations and should not be used in lieu of a customer valuation statement or account statement. These values may not reflect the value of the positions carried on the books and records of Goldman Sachs or its affiliates and should not be relied upon for the maintenance of your books and records or for any tax, accounting, legal or other purposes. The information provided herein does not supersede any customer statements, confirmations or other similar notifications.
- **Indicative Terms/Pricing Levels:** This material may contain indicative terms only, including but not limited to pricing levels. There is no representation that any transaction can or could have been effected at such terms or prices. Proposed terms and conditions are for discussion purposes only. Finalized terms and conditions are subject to further discussion and negotiation.
- **Backtesting, Simulated Results, Sensitivity/Scenario Analysis or Spreadsheet Calculator or Model:** There may be data presented herein that is solely for illustrative purposes and which may include among other things back testing, simulated results and scenario analyses. The information is based upon certain factors, assumptions and historical information that Goldman Sachs may in its discretion have considered appropriate, however, Goldman Sachs provides no assurance or guarantee that this product will operate or would have operated in the past in a manner consistent with these assumptions. In the event any of the assumptions used do not prove to be true, results are likely to vary materially from the examples shown herein. Additionally, the results may not reflect material economic and market factors, such as liquidity, transaction costs and other expenses which could reduce potential return.
- **Order Handling Practices for Listed and Over-the-Counter Derivatives:** While the firm is holding your derivative (e.g. options, convertible bonds, warrants or preferred shares) order, the firm or its clients may engage in trading activity in the same or related products, including transactions in the underlying securities. While such trading activity is unrelated to your order, it may coincidentally impact the price of the derivative that you are buying or selling.
- **OTC Derivatives Risk Disclosures: Terms of the Transaction:** To understand clearly the terms and conditions of any OTC derivative transaction you may enter into, you should carefully review the Master Agreement, including any related schedules, credit support documents, addenda and exhibits. You should not enter into OTC derivative transactions unless you understand the terms of the transaction you are entering into as well as the nature and extent of your risk exposure. You should also be satisfied that the OTC derivative transaction is appropriate for you in light of your circumstances and financial condition. You may be requested to post margin or collateral to support written OTC derivatives at levels consistent with the internal policies of Goldman Sachs.

**Liquidity Risk:** There is no public market for OTC derivative transactions and, therefore, it may be difficult or impossible to liquidate an existing position on favorable terms.

**Transfer Restrictions:** OTC derivative transactions entered into with one or more affiliates of The Goldman Sachs Group, Inc. (Goldman Sachs) cannot be assigned or otherwise transferred without its prior written consent and, therefore, it may be impossible for you to transfer any OTC derivative transaction to a third party.

**Conflict of Interests:** Goldman Sachs may from time to time be an active participant on both sides of the market for the underlying securities, commodities, futures, options or any other derivative or instrument identical or related to those mentioned herein (together, "the Product"). Goldman Sachs at any time may have long or short positions in, or buy and sell Products (on a principal basis or otherwise) identical or related to those mentioned herein. Goldman Sachs hedging and trading activities may affect the value of the Products.

**Counterparty Credit Risk:** Because Goldman Sachs, may be obligated to make substantial payments to you as a condition of an OTC derivative transaction, you must evaluate the credit risk of doing business with Goldman Sachs or its affiliates.

- **Pricing and Valuation:** The price of each OTC derivative transaction is individually negotiated between Goldman Sachs and each counterparty and Goldman Sachs does not represent or warrant that the prices for which it offers OTC derivative transactions are the best prices available, possibly making it difficult for you to establish what is a fair price for a particular OTC derivative transaction; The value or quoted price of the Product at any time, however, will reflect many factors and cannot be predicted. If Goldman Sachs makes a market in the offered Product, the price quoted by Goldman Sachs would reflect any changes in market conditions and other relevant factors, and the quoted price (and the value of the Product that Goldman Sachs will use for account statements or otherwise) could be higher or lower than the original price, and may be higher or lower than the value of the Product as determined by reference to pricing models used by Goldman Sachs. If at any time a third party dealer quotes a price to purchase the Product or otherwise values the Product, that price may be significantly different (higher or lower) than any price quoted by Goldman Sachs. Furthermore, if you sell the Product, you will likely be charged a commission for secondary market transactions, or the price will likely reflect a dealer discount. Goldman Sachs may conduct market making activities in the Product. To the extent Goldman Sachs makes a market, any price quoted for the OTC derivative transactions, Goldman Sachs may differ significantly from (i) their value determined by reference to Goldman Sachs pricing models and (ii) any price quoted by a third party. The market price of the OTC derivative transaction may be influenced by many unpredictable factors, including economic conditions, the creditworthiness of Goldman Sachs, the value of any underlyers, and certain actions taken by Goldman Sachs.

**Market Making, Investing and Lending:** Goldman Sachs engages in market making, investing and lending businesses for its own account and the accounts of its affiliates in the same or similar instruments underlying OTC derivative transactions (including such trading as Goldman Sachs deems appropriate in its sole discretion to hedge its market risk in any OTC derivative transaction whether between Goldman Sachs and you or with third parties) and such trading may affect the value of an OTC derivative transaction.

**Early Termination Payments:** The provisions of an OTC Derivative Transaction may allow for early termination and, in such cases, either you or Goldman Sachs may be required to make a potentially significant termination payment depending upon whether the OTC Derivative Transaction is in-the-money to Goldman Sachs or you at the time of termination.

**Indexes:** Goldman Sachs does not warrant, and takes no responsibility for, the structure, method of computation or publication of any currency exchange rates, interest rates, indexes of such rates, or credit, equity or other indexes, unless Goldman Sachs specifically advises you otherwise.

- © 2019 Goldman Sachs. All rights reserved.
- Prepared by a Goldman Sachs sales and trading desk, which may have a position in the products mentioned that is inconsistent with the views expressed in this material. In evaluating this material, you should know that it could have been previously provided to other clients and/or internal Goldman Sachs personnel, who could have already acted on it. The views or ideas expressed here are those of the desk and/or author only and are not an "official view" of Goldman Sachs; others at Goldman Sachs may have opinions or may express views that are contrary to those herein. This material is not an investment recommendation and is not a product of Global Investment Research. To the extent this material is subject to Article 52 of the Markets in Financial Instruments Directive Implementing Directive (2006/73/EC), notwithstanding any statements elsewhere in this communication, you are receiving this communication from the relevant sales desk or author on the basis of your investment objectives or trading strategy. If you have any questions please contact your GS representative. This material is a solicitation of derivatives business generally, only for the purposes of, and to the extent it would otherwise be subject to, CFTC Regulations 1.71 and 23.605.

You are responsible for assessing the commercial benefits and implications of any recommendations that we make to you. In particular, we do not provide legal, accounting or tax advice and you are strongly advised to consult your own independent advisers on any legal, tax or accounting issues relating to this matter. Any tailored content we send to you is exclusively for your information, and may not be disclosed to any third party or circulated or referred to publicly without our prior written consent. Please note that we may send the same tailored content to a number of our clients where we believe that content also meets their investment objectives or trading strategy.